Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia

Atherosclerosis

Volumn 73, Issue 2-3, 1988, Pages 135-141

  Leren, Trond P ^a   Hjermann, Ingvar ^b   Berg, Kåre ^a,c   Leren, Paul ^b   Foss, Olav P ^b   Viksmoen, Lars ^d  

^a Department of Medical Genetics City of Oslo Norway ^*

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d Merck Sharp and Dohme ^*

Author keywords

Apolipoproteins; Cholestyramine; Familial hypercholesterolemia; Lipids; Lipoproteins; Lovastatin

Indexed keywords

APOLIPOPROTEIN; COLESTYRAMINE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; TRIACYLGLYCEROL;

ADULT; CLINICAL ARTICLE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEINS; CHOLESTYRAMINE; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA, FAMILIAL; LIPIDS; LOVASTATIN; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T;

EID: 0023785197     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(88)90034-2     Document Type: Article

References (31)

1. Treatment of hypercholesterolemia
2. A receptor-mediated pathway for cholesterol homeostasis
3. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism
4. Mevinolin and colestipol stimulate receptormediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes
5. Mevinohn — a highly potent competitive inhibitor of hydroxymethylglutarylcoenzyme A reductase and a cholesterol lowering agent
6. The hyperlipoproteinemias and other disorders of lipid metabolism
7. Smoking and diet intervention in healthy coronary high risk men. Methods and 5-year follow-up of risk factors in a randomized trial
8. Enzymatische Bestimmung des Gesamt-Cholesterins im Serum
9. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions
10. High density lipoprotein cholesterol and myocardial infarction and sudden death: a prospective case-control study in middle aged men in Oslo
11. Eine neue Bestimmung der Neutralfette im Blutserum and Gewebe
12. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol
13. Presence of “free” apoA-I in serum: implications for immunological quantification of HDL and its apoproteins
14. The effect of gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity (SRCBC)
15. Inherited lipoprotein variation and atherosclerotic disease
16. Lp(a) lipoprotein as a risk factor for myocardial infarction
17. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia
18. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia
19. Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia
20. Effect of lipid lowering diet on low density lipoprotein receptor activity in freshly isolated peripheral blood mononuclear cells
21. Lovastatin (Mevinolin) in the treatment of heterozygous familial hypercholesterolemia
22. Molecular weights of apoprotein B obtained from human low-density lipoprotein (apoprotein B-PI) and from rat very low density lipoprotein (apoprotein B-PIII)
23. Familial lipoprotein deficiency: abetalipoproteinemia, hypobetalipoproteinemia, and Tangier disease
24. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a)
25. The Lipid Research Clinics coronary primary prevention trial results I Reduction in incidence of coronary heart disease
26. The effect of mevinolin on steroidogenesis in patients with defect in the low density lipoprotein receptor pathway
27. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia
28. Levels of lipoprotein Lp(a) decline with Neomycin and Niacin treatment
29. Radioimmunoassay of human plasma Lp(a) lipoprotein
30. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins Al, All and B and LCAT activity in hyperlipidemic non-insulin dependent diabetics